Insider
Mckesson CorpMCK

McKesson second-quarter results: revenue up 8% to $111 billion

McKesson Corporation reported preliminary results for the quarter ended September 30, 2026. Consolidated revenue grew 8% to $111 billion. Earnings per diluted share (EPS) for the period were $10.44, up $1.52 from the year-ago quarter.

Verified against 3 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
a long hallway with pictures on the walls
Photo by zhang shuaizhang on Unsplash
$111 billion
Quarterly revenue
$10.44
Earnings per diluted share
8%
Revenue growth, y/y

Key points

  • Key business segments drove the 8% revenue growth.
  • Quarterly financial results include costs from restructuring and corporate initiatives.

Financial results and strategic initiatives

Key business segments drove the 8% revenue growth. North American Pharmaceutical Services revenue was $91.4 billion (up 6%), Oncology & Multispecialty Services revenue was $15 billion (up 24%), and Prescription Technology Solutions revenue was $1.5 billion (up 10%). The Medical-Surgical Solutions segment grew 5% to $3.1 billion in revenue.

The company completed several strategic moves. It extended its pharmaceutical distribution partnership with CVS Health through June 2032, signed a $1.4 billion deal for a minority stake in Option Care Health, Inc., and finalized its acquisition of Precision Medicine Group, LLC.

Revenue by quarter, $B

95.3Q3 '251.3%90.8Q4 '25*1.8%97.8Q1 '261.1%103Q2 '261.4%106Q3 '261.5%96.3Q4 '26*2.2%105Q1 '271.3%111Q2 '271.4%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Impact of restructuring costs

Quarterly financial results include costs from restructuring and corporate initiatives. The Prescription Technology Solutions segment incurred $18 million in restructuring costs, while the Medical-Surgical Solutions segment recorded $42 million in net charges related to the planned separation of that business.

Outlook

Investors should monitor future company reports and quarterly materials to track how restructuring costs and the integration of Precision Medicine Group affect future financial performance.

Original sources

  1. 8-K filing, November 4, 2026November 4, 2026SHA-256 of our archived copy b8d331a31ea0…
  2. 8-K EX-99.1 filing, November 4, 2026November 4, 2026SHA-256 of our archived copy 7672579e7a1d…
  3. 10-Q filing, November 4, 2026November 4, 2026SHA-256 of our archived copy cdd9e9db109b…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards